Hasil Pencarian - Simon Rule

  • Menampilkan 1 - 17 hasil dari 17
Perbaiki Hasil
  1. 1
    Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin

    Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin oleh Michelle Furtado, Simon Rule

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin

    Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin oleh Michelle Furtado, Simon Rule

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Indolent mantle cell lymphoma

    Indolent mantle cell lymphoma oleh Michelle Furtado, Simon Rule

    Diterbitkan 2011-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Reducing Bureaucracy in Clinical Research: A Call for Action

    Reducing Bureaucracy in Clinical Research: A Call for Action oleh John Gribben, Elizabeth Macintyre, Pieter Sonneveld, Jeanette Doorduijn, Christian Gisselbrecht, Ulrich Jäger, Steven Le Gouill, Simon Rule, Martin Dreyling

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

    Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma oleh Andrew Grigg, Martin J.S. Dyer, Marcos González Díaz, Martin Dreyling, Simon Rule, Guiyuan Lei, Andrea Knapp, Elisabeth Wassner-Fritsch, Paula Marlton

    Diterbitkan 2017-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis oleh Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, José-Ángel Hernández-Rivas, Keqin Qi, Sanjay Deshpande, Lori Parisi, Michael Wang

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) oleh Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study oleh Paolo Strati, Sven de Vos, Jia Ruan, Kami J. Maddocks, Christopher R. Flowers, Simon Rule, Priti Patel, Yan Xu, Helen Wei, Melanie M. Frigault, Roser Calvo, Martin J.S. Dyer

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.

    P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION. oleh Steven Le Gouill, Franck Morschhauser, David Chiron, Kamal Bouabdallah, Guillaume Cartron, Rene Olivier Casasnovas, Caroline Milin, Charles Herbaux, Emmanuelle Tchernonog, Cedric Rossi, Simon Rule, Thomas Gastinne, Mary Callanan, Benoit Tessoulin

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study

    Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III... oleh Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo M. Carella, Olivier Casasnovas, Chris Pocock, Clemens-Martin Wendtner, Francesco Zaja, Susan Robson, Lachlan MacGregor, Roger R. Tschopp, Sonja Nick, Martin Dreyling

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: 2 approved]

    ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for... oleh Andrew Davies, Sharon Barrans, Cathy Burton, Katy Mercer, Joshua Caddy, Fay Chinnery, Laura Day, Diana Fernando, Kirit Ardeshna, Graham Collins, John Radford, Simon Rule, Andrew McMillan, Peter Johnson, Gareth Griffiths

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

    Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial oleh Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, Anthony Lawrie, Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew K. McMillan

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial

    The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lym... oleh Simon Rule, Paul Smith, Peter W.M. Johnson, Simon Bolam, George Follows, Joanne Gambell, Peter Hillmen, Andrew Jack, Stephen Johnson, Amy A Kirkwood, Anton Kruger, Christopher Pocock, John F. Seymour, Milena Toncheva, Jan Walewski, David Linch

    Diterbitkan 2016-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Is Good Clinical Practice Becoming Poor Clinical Care?

    Is Good Clinical Practice Becoming Poor Clinical Care? oleh Steven Le Gouill, Martin Dreyling, Maria Dolores Caballero, Marc Andre, Jeannette Doorduijn, Wojciech Jurczak, Mats Jerkeman, Paolo Ghia, Pier-Luigi Zinzani, Maria Gomez Da Silva, Meletios Dimopoulos, Marek Trneny, Richard Delarue, Jan Walewski, Christian Gisselbrecht, Armando López-Guillermo, Simon Rule

    Diterbitkan 2017-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

    Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial oleh Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie‐Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

    Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prog... oleh Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials oleh Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: